{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T18:13:02Z","timestamp":1789150382388,"version":"build-2803163510"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,6,23]],"date-time":"2023-06-23T00:00:00Z","timestamp":1687478400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Nucl. Med."],"abstract":"<jats:p>There is a growing use of radionuclide therapy for the medical care of oncology patients, where radioactive pharmaceuticals are used to target and treat various cancer types. This paper provides a brief overview illustrating the spectrum of ongoing and recently completed radionuclide therapy clinical trials in oncology. The trials selected highlight the potential of radionuclide therapies to provide a promising treatment option across a spectrum of cancer patients, while also discussing the importance of patient selection and monitoring, as well as potential side effects and safety concerns. Ultimately, the results of these trials will be crucial in determining the future use of radionuclide therapies in cancer treatment.<\/jats:p>","DOI":"10.3389\/fnume.2023.1169650","type":"journal-article","created":{"date-parts":[[2023,6,24]],"date-time":"2023-06-24T09:38:42Z","timestamp":1687599522000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["A brief overview of targeted radionuclide therapy trials in 2022"],"prefix":"10.3389","volume":"3","author":[{"given":"Aidan","family":"Healy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Zukotynski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,6,23]]},"reference":[{"key":"B1","year":""},{"key":"B2","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1007\/s00259-012-2330-6","article-title":"The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours","volume":"40","author":"Bodei","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B3","doi-asserted-by":"publisher","first-page":"103","DOI":"10.7150\/ntno.64141","article-title":"Radiotheranostics\u2014precision medicine in nuclear medicine and molecular imaging","volume":"6","author":"Duan","year":"2022","journal-title":"Nanotheranostics"},{"key":"B4","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1053\/j.semnuclmed.2022.12.007","article-title":"Molecular imaging theranostics of neuroendocrine tumors","volume":"53","author":"Fortunati","year":"2023","journal-title":"Semin Nucl Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s11307-017-1151-1","article-title":"Prostate cancer theranostics targeting gastrin-releasing peptide receptors","volume":"20","author":"Baratto","year":"2018","journal-title":"Mol Imaging Biol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.annonc.2020.03.304","article-title":"Gastroenteropancreatic neuroendocrine neoplasms: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Pavel","year":"2020","journal-title":"Ann Oncol"},{"key":"B8","author":"O\u2019Dorisio","year":"2017"},{"key":"B9","year":"2019"},{"key":"B10","author":"Galgano","year":"2018"},{"key":"B11","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/S1470-2045(18)30198-0","article-title":"[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study","volume":"19","author":"Hofman","year":"2018","journal-title":"Lancet Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1536012118776068","DOI":"10.1177\/1536012118776068","article-title":"PSMA theranostics: current status and future directions","volume":"17","author":"Rahbar","year":"2018","journal-title":"Mol Imaging"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.2967\/jnumed.116.178673","article-title":"Ac-225-PSMA-617 for PSMA-targeted \u03b1-radiation therapy of metastatic castration-resistant prostate cancer","volume":"57","author":"Kratochwil","year":"2016","journal-title":"J Nucl Med"},{"key":"B14","year":"2018"},{"key":"B15","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","article-title":"[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial","volume":"397","author":"Hofman","year":"2021","journal-title":"Lancet"},{"key":"B16","year":""},{"key":"B17","year":"2023"},{"key":"B18","year":"2022"},{"key":"B19","author":"Prior","year":"2023"},{"key":"B20","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1002\/path.2207","article-title":"FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer","volume":"213","author":"Tomlinson","year":"2007","journal-title":"J Pathol"},{"key":"B21","year":"2022"},{"key":"B22","year":"2021"},{"key":"B23","year":"2022"},{"key":"B24","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1053\/j.semnuclmed.2016.01.010","article-title":"Peptide receptor radionuclide therapy (PRRT) of medullary and nonmedullary thyroid cancer using radiolabeled somatostatin analogues","volume":"46","author":"Salavati","year":"2016","journal-title":"Semin Nucl Med"},{"key":"B25","year":"2022"},{"key":"B26","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3390\/antib9040059","article-title":"CD46 and oncologic interactions: friendly fire against cancer","volume":"9","author":"Elvington","year":"2020","journal-title":"Antibodies (Basel)"},{"key":"B27","author":"Flavell","year":"2022"},{"key":"B28","year":"2022"}],"container-title":["Frontiers in Nuclear Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnume.2023.1169650\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T09:56:53Z","timestamp":1728035813000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnume.2023.1169650\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,23]]},"references-count":28,"alternative-id":["10.3389\/fnume.2023.1169650"],"URL":"https:\/\/doi.org\/10.3389\/fnume.2023.1169650","relation":{},"ISSN":["2673-8880"],"issn-type":[{"value":"2673-8880","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,23]]},"article-number":"1169650"}}